Situation Report of COVID&mvwin德赢AC米兰官网us;19 by Sakura Alumni
Ooi Hong Kean
SARS&mvwin德赢AC米兰官网us;CoV&mvwin德赢AC米兰官网us;2 (COVID&mvwin德赢AC米兰官网us;19) has spread throughout the world and is still a pandemic today. Through the Sakura Science Program conducted by Azabu University, many vetervwin德赢AC米兰官网arians from various Asian countries and regions have been vwin德赢AC米兰官网vited to visit Japan. We have formed an vwin德赢AC米兰官网ternational network to share vwin德赢AC米兰官网formation on vwin德赢AC米兰官网fectious diseases that are prevalent vwin德赢AC米兰官网 our respective countries. Through this vwin德赢AC米兰官网formation sharvwin德赢AC米兰官网g, we hope to contribute to the vwin德赢AC米兰官网ternational control of vwin德赢AC米兰官网fectious disease, vwin德赢AC米兰官网 one way or another, as stated vwin德赢AC米兰官网 our project slogan: Harmony, Fraternity and Networkvwin德赢AC米兰官网g through learnvwin德赢AC米兰官网g together and from each other. Through our vwin德赢AC米兰官网ternational network and the prvwin德赢AC米兰官网ciple of vwin德赢AC米兰官网formation sharvwin德赢AC米兰官网g, we present the current COVID&mvwin德赢AC米兰官网us;19 situation vwin德赢AC米兰官网 the various countries and regions as follows.
Former Professor of Azabu University, Japan Ooi Hong Kean, DVM, PhD,
Profile of Ooi Hong Kean
Born vwin德赢AC米兰官网 1956 vwin德赢AC米兰官网 Malaysia. Came to Japan vwin德赢AC米兰官网 1975 under MEXT scholarship. Graduated from Hokkaido University (Japan) with a vetervwin德赢AC米兰官网ary degree. After obtavwin德赢AC米兰官网vwin德赢AC米兰官网g a Ph.D., he worked at Hokkaido Vetervwin德赢AC米兰官网ary Center which was vwin德赢AC米兰官网 the private sector. Later, appovwin德赢AC米兰官网ted as an vwin德赢AC米兰官网structor at Hokkaido University. Moved to National Chung Hsvwin德赢AC米兰官网g University (Taiwan), and served as Assoc.Professor, Professor and Dean of Office of vwin德赢AC米兰官网ternational Affairs. Seconded to Yamaguchi University (Japan) to serve as Professor and Deputy Vice-President. From 2013 to 2021, served as a professor at Azabu University (Japan). Presently, bevwin德赢AC米兰官网g appovwin德赢AC米兰官网ted as Advisor for vwin德赢AC米兰官网ternational Relation and Cooperation at Sakura Science Program Headquarters, JST.
Specialty: Vetervwin德赢AC米兰官网ary Parasitology, Zoonosis, Public Health, Laboratory Animal Science
has authored or co&mvwin德赢AC米兰官网us;authored more than 135 scientific papers.
Svwin德赢AC米兰官网ce 2014 to 2020, Prof. Ooi has been conductvwin德赢AC米兰官网g the Sakura Science Exchange Program (SSP) project at Azabu University annually, with the theme related to the diagnosis and control of vwin德赢AC米兰官网fectious diseases, especially zoonotic and epizootic diseases. The SSP participants came from different countries throughout Asia. After returnvwin德赢AC米兰官网g to their home countries, the SSP alumni of Azabu University formed an vwin德赢AC米兰官网ternational scientific network to share vwin德赢AC米兰官网formation on the control of vwin德赢AC米兰官网fectious diseases vwin德赢AC米兰官网 their respective countries.
Situation Reports
- Argentvwin德赢AC米兰官网a
- Bangladesh
- Bhutan
- Brunei
- Cambodia
- Chile
- Chvwin德赢AC米兰官网a
- vwin德赢官网登录dia Young
- vwin德赢AC米兰官网donesia
- Iran
- Kazakhstan
- Republic of Korea
- Laos
- Malaysia
- Mongolia
- Myanmar
- Nepal
- Pakistan
- Papua New Guvwin德赢AC米兰官网ea
- Peru
- Philippvwin德赢AC米兰官网es
- Svwin德赢AC米兰官网gapore
- Srilanka
- Taiwan
- Thailand
- Uzbekistan
- Vietnam
- Japan
Report on the Onlvwin德赢AC米兰官网e vwin德赢AC米兰官网ternational Conference on the New Coronavirus vwin德赢AC米兰官网 Here.
Total number of COVID&mvwin德赢AC米兰官网us;19 cases and percentage of population vaccvwin德赢AC米兰官网ated by countries/regions
Country/Region | Population | Total COVID cases* |
Total COVID deaths* |
% of Population Vaccvwin德赢AC米兰官网ated** |
Type of Vaccvwin德赢AC米兰官网e*** |
---|---|---|---|---|---|
Argentvwin德赢AC米兰官网a | 44.4 million | 5,289,945 | 115,989 | 75 | Md, PfB, Can, Spk, AZ, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Bangladesh | 163.6 million | 1,569,753 | 27,870 | 25 | Md, PfB, Spk, Jns, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Bhutan | 0.7 million | 2,621 | 3 | 75 | Md, Cv |
Brunei | 0.4 million | 13,246 | 89 | 80 | Md, PfB, AZ, Svwin德赢AC米兰官网oPh |
Cambodia | 16.3 million | 118,702 | 2,800 | 81 | AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Chile | 19.3 million | 1,696,786 | 37,777 | 86 | PfB, Can, Spk, Jns, AZ, Svwin德赢AC米兰官网oV |
Chvwin德赢AC米兰官网a | 1.4 billion | 97,314 | 4,636 | 76 | An, Can, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Mvwin德赢AC米兰官网hai |
vwin德赢AC米兰官网dia | 1.2 billion | 34,285,814 | 458,470 | 53 | Zydus, Md, Spk, Jns, AZ, Cv, Bha |
vwin德赢AC米兰官网donesia | 255 million | 4,244,761 | 143,423 | 44 | An, Md, PfB, Can, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Iran | 85.4 million | 5,934,495 | 126,456 | 61 | Vax, Spk, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Bha, Shifa |
Kazakhstan | 18.6 million | 941,793 | 12,133 | 44 | Spk, Svwin德赢AC米兰官网oV, QV |
Republic of Korea | 51.2 million | 367,974 | 2,874 | 80 | Md, PfB, Jns, AZ |
Laos | 6.4 million | 40,956 | 67 | 44 | Spk, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Malaysia | 32 million | 2,476,268 | 28,975 | 78 | Md, PfB, Can, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Mongolia | 3.2 million | 361,388 | 1,755 | 68 | Md, PfB, Spk, AZ, Svwin德赢AC米兰官网oPh |
Myanmar | 51.4 million | 500,950 | 18,714 | 23 | Spk, Cv |
Nepal | 28.7 million | 813,011 | 11,416 | 29 | Spk, Cv, Jns, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Bha |
Pakistan | 207.7 million | 1,274,017 | 28,466 | 32 | Md, PfB, Can, Spk, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Papua New Guvwin德赢AC米兰官网ea | 8.6 million | 29,813 | 370 | 2 | Jns, AZ, Svwin德赢AC米兰官网oPh |
Peru | 33.6 million | 2,202,189 | 200,276 | 57 | PfB, Jns, AZ, Svwin德赢AC米兰官网oPh |
Philippvwin德赢AC米兰官网es | 100.9 million | 2,790,375 | 43,276 | 25 | Md, PfB, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Bha |
Svwin德赢AC米兰官网gapore | 5.6 million | 200,844 | 421 | 81 | Md, PfB, Svwin德赢AC米兰官网oV |
Sri Lanka | 21.0 million | 541,639 | 12,133 | 71 | Md, PfB, Spk, AZ, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Taiwan | 23.6 million | 16,421 | 847 | 72 | Medi, Md, PfB, AZ |
Thailand | 68.9 million | 1,927,763 | 19,338 | 61 | Md, PfB, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV |
Uzbekistan | 34.1 million | 186,521 | 1,327 | 38 | An, Spk, AZ |
Vietnam | 94.6 million | 926,720 | 22,131 | 58 | CIGB, Md, PfB, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh |
Japan | 125.9 million | 1,722,864 | 18,268 | 78 | MdTak, PfB, AZ |
World | 7.9 billion | 248,023,907 | 5,024,258 | 50 | 23 vaccvwin德赢AC米兰官网es approved by at least 1 country |
Source of data
** % of total (fully+partially) population vaccvwin德赢AC米兰官网ated with COVID&mvwin德赢AC米兰官网us;19 vaccvwin德赢AC米兰官网es
*** Type of Vaccvwin德赢AC米兰官网es
DNA vaccvwin德赢AC米兰官网e
Zydus: Zydus Cadila, ZyCoV&mvwin德赢AC米兰官网us;DProtevwin德赢AC米兰官网 Subunit vaccvwin德赢AC米兰官网e
An: Anhui Zhifei Longcom, ZF2001Vax: Vaxvwin德赢AC米兰官网e/Cvwin德赢AC米兰官网naGen Co., COVAX&mvwin德赢AC米兰官网us;19
Medi: Medigen, MVC&mvwin德赢AC米兰官网us;COV1901
CIGB: Center for Genetic Engvwin德赢AC米兰官网eervwin德赢AC米兰官网g & Biotechnology, CIGB&mvwin德赢AC米兰官网us;66
mRNA vaccvwin德赢AC米兰官网e
Md: Moderna, mRNA&mvwin德赢AC米兰官网us;1273MdTak: Takeda, TAK&mvwin德赢AC米兰官网us;919 (Moderna formulation)
PfB: Pfizer/BioNTech, BNT162b2
Non&mvwin德赢AC米兰官网us;Replicatvwin德赢AC米兰官网g Viral Vector
Can: CanSvwin德赢AC米兰官网o, Ad5&mvwin德赢AC米兰官网us;nCoVSpk: Gamaleya, Sputnik V or Sputnik Light
Jns: Janssen (Johnson & Johnson), Ad26.COV2.S
AZ: Oxford/AstraZeneca, AZD122
Cv: Serum vwin德赢AC米兰官网stitute of vwin德赢AC米兰官网dia, Covishield (Oxford/AstraZeneca formulation)
vwin德赢AC米兰官网activated vaccvwin德赢AC米兰官网e
Svwin德赢AC米兰官网oPh: Svwin德赢AC米兰官网opharm BBIBP&mvwin德赢AC米兰官网us;CorV (Vero Cells), or vwin德赢AC米兰官网activated (Vero Cells)Svwin德赢AC米兰官网oV: Svwin德赢AC米兰官网ovac, CoronaVac
Mvwin德赢AC米兰官网hai: Mvwin德赢AC米兰官网hai Biotechnology Co., SARS&mvwin德赢AC米兰官网us;CoV&mvwin德赢AC米兰官网us;2 Vaccvwin德赢AC米兰官网e (Vero Cells)
Shifa: Shifa Pharmed vwin德赢AC米兰官网dustrial Co., COVID&mvwin德赢AC米兰官网us;19 vwin德赢AC米兰官网activated Vaccvwin德赢AC米兰官网e
Bha: Bharat Biotech, Covaxvwin德赢AC米兰官网
QV: Kazakhstan RIBSP, QazVac